Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with paten ductus arterious (PDA)

T. F. Yeh, D. Raval, S. Pyati, S. Pildes

研究成果: 雜誌貢獻文章同行評審

13 引文 斯高帕斯(Scopus)

摘要

Recent studies suggested that prostaglandins (PGs) may play a role in the pathogenesis of retinopathy of prematuriry (ROP). To evaluate if PGs inhibitor, indomethacin, would affect the incidence or severity of the ble-blind controlled study of indomethacin for the closure of PDA. Twenty-three were in the control group and 24 in the indometchin group. Indirect ophthalmospic examinations wee performed from about 4 weeks of postnatal age and onward and needed. There was no significant differences between the groups with respect to birth weight, gestational age, postnatal age, Apgar score, and cardiopulmonary status shortly after birth and at the time of study. Six in the control and 2 in the indomethacin group (p=0.58) developed active ROP; one in each group developed cicatricial ROP. It appears that with current doses of therapy, indomethacin does not increase the incidence or severity of ROP.

原文英語
頁(從 - 到)385-391
頁數7
期刊Prostaglandins
25
發行號3
DOIs
出版狀態已發佈 - 一月 1 1983
對外發佈Yes

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

指紋 深入研究「Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with paten ductus arterious (PDA)」主題。共同形成了獨特的指紋。

引用此